PMID- 29211611 OWN - NLM STAT- MEDLINE DCOM- 20190903 LR - 20220527 IS - 1532-4303 (Electronic) IS - 0277-0903 (Linking) VI - 55 IP - 10 DP - 2018 Oct TI - Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab. PG - 1116-1121 LID - 10.1080/02770903.2017.1396471 [doi] AB - BACKGROUND: Remodeling is a crucial feature of severe asthma and may be associated with activation of the allergic cascade by immunoglobulin E (IgE). Omalizumab, an anti-IgE monoclonal antibody, effectively targets the severe allergic asthma phenotype. Pregnancy-associated plasma protein-A (PAPP-A) is an insulin-like growth factor binding protein-4 (IGFBP-4) protease, increasing local insulin-like growth factor (IGF)-1 concentrations, which in turn initiating a cascade involved in the regulation of cell growth, differentiation, and proliferation in various tissues. In the present study, we evaluated the effects of omalizumab on serum PAPP-A, IGFBP-4, and IGF-1 levels in subjects with severe allergic asthma. METHODS: We studied 36 asthmatic subjects and 36 healthy controls. An ultrasensitive enzyme-linked immunosorbent assay (ELISA) kit was used to measure serum PAPP-A levels, and routine commercial ELISA kits were employed to assess serum levels of IGF-1, IGFBP-4 in control subjects and asthmatic subjects before therapy (baseline) and after six months of omalizumab therapy in patients with severe asthma. RESULTS: Compared to control subjects, serum PAPP-A and IGFB-4 levels were significantly higher in asthmatic subjects (both p values < 0.001). However, the serum IGF-I levels of asthmatic subjects were similar to those of control subjects (p > 0.05). In asthma subjects, 6-month omalizumab treatment significantly decreased the serum PAPP-A (p < 0.001), IGF-I (p = 0.031), and IGFB4 (p = 0.025) levels. CONCLUSION: PAPP-A level may be a useful biomarker for predicting airway remodeling in patients with severe asthma receiving omalizumab, and may also reflect the response to treatment. FAU - Bulut, Ismet AU - Bulut I AD - a Health Science University, Sureyyapasa Chest Disease and Chest Surgery Research and Training Hospital , Department of Immunology and Allergy Disease , Istanbul , Turkey. FAU - Ozseker, Zeynep F AU - Ozseker ZF AD - c Istanbul University, Cerrahpasa Faculty of Medicine , Department of Chest Disease Istanbul , Turkey. FAU - Coskun, Abdurrahman AU - Coskun A AD - b Acibadem University, Faculty of Medicine , Department of Medical Biochemistry , Istanbul , Turkey. FAU - Serteser, Mustafa AU - Serteser M AD - b Acibadem University, Faculty of Medicine , Department of Medical Biochemistry , Istanbul , Turkey. FAU - Unsal, Ibrahim AU - Unsal I AD - b Acibadem University, Faculty of Medicine , Department of Medical Biochemistry , Istanbul , Turkey. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20171206 PL - England TA - J Asthma JT - The Journal of asthma : official journal of the Association for the Care of Asthma JID - 8106454 RN - 2P471X1Z11 (Omalizumab) RN - 37341-29-0 (Immunoglobulin E) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A) SB - IM MH - Adult MH - Asthma/*drug therapy MH - Dose-Response Relationship, Drug MH - Enzyme-Linked Immunosorbent Assay MH - Humans MH - Immunoglobulin E/drug effects MH - Insulin-Like Growth Factor I/*drug effects MH - Middle Aged MH - Omalizumab/pharmacology/*therapeutic use MH - Pregnancy-Associated Plasma Protein-A/*drug effects MH - Respiratory Function Tests MH - Severity of Illness Index MH - Socioeconomic Factors OTO - NOTNLM OT - Allergy OT - asthma OT - inflammation OT - omalizumab OT - pregnancy-associated plasma protein A EDAT- 2017/12/07 06:00 MHDA- 2019/09/04 06:00 CRDT- 2017/12/07 06:00 PHST- 2017/12/07 06:00 [pubmed] PHST- 2019/09/04 06:00 [medline] PHST- 2017/12/07 06:00 [entrez] AID - 10.1080/02770903.2017.1396471 [doi] PST - ppublish SO - J Asthma. 2018 Oct;55(10):1116-1121. doi: 10.1080/02770903.2017.1396471. Epub 2017 Dec 6.